Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)

Efficacy of the CCR5 Antagonist Maraviroc in Reducing Early, Ritonavir-Induced Atherogenesis and Advanced Plaque Progression in Mice

(2013) Sabrina Cipriani et al.   CIRCULATION

Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation

(2013) Julieta Díaz-Delfín et al.   CYTOKINE

Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice

(2013) Neta Barashi et al.   HEPATOLOGY

Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model

(2013) Laura Ochoa-Callejero et al.   PLoS One

Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens

(2012) Alba Bigoloni et al.   AIDS

CCR5 Plays a Critical Role in Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance by Regulating Both Macrophage Recruitment and M1/M2 Status

(2012) H. Kitade et al.   DIABETES

Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients

(2012) Juan Macías et al.   HEPATOLOGY

Lipoic acid administration prevents nonalcoholic steatosis linked to long-term high-fat feeding by modulating mitochondrial function

(2012) M. Pilar Valdecantos et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Role of cytokines and chemokines in non-alcoholic fatty liver disease

(2012) Vincent Braunersreuther   WORLD JOURNAL OF GASTROENTEROLOGY

Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial

(2011) A. MacInnes et al.   HIV CLINICAL TRIALS

RANTES antagonism: A promising approach to treat chronic liver diseases

(2011) Silvia Affò et al.   JOURNAL OF HEPATOLOGY

Increasing burden of liver disease in patients with HIV infection

(2011) Deepak Joshi et al.   LANCET

Human Fatty Liver Disease: Old Questions and New Insights

(2011) J. C. Cohen et al.   SCIENCE

Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors

(2010) Mariana Verdelho Machado et al.   HEPATOLOGY

Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice

(2010) Marie-Luise Berres et al.   JOURNAL OF CLINICAL INVESTIGATION

A position statement on NAFLD/NASH based on the EASL 2009 special conference

(2010) Vlad Ratziu et al.   JOURNAL OF HEPATOLOGY

Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice

(2010) Kanji Yamaguchi et al.   LABORATORY INVESTIGATION

The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice

(2010) Livia de Fraia Pinto et al.   LIVER INTERNATIONAL

Functional role of chemokines in liver disease models

(2010) Hacer Sahin et al.   Nature Reviews Gastroenterology & Hepatology

Hepatic Expression Patterns of Inflammatory and Immune Response Genes Associated with Obesity and NASH in Morbidly Obese Patients

(2010) Adeline Bertola et al.   PLoS One

Oral Pre-Exposure Prophylaxis by Anti-Retrovirals Raltegravir and Maraviroc Protects against HIV-1 Vaginal Transmission in a Humanized Mouse Model

(2010) C. Preston Neff et al.   PLoS One

Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis

(2008) Anna Wieckowska et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes

(2008) C. Pfleger et al.   CLINICAL IMMUNOLOGY

Atherogenic diet-induced hepatitis is partially dependent on murine TLR4

(2008) M. S. Desai et al.   JOURNAL OF LEUKOCYTE BIOLOGY